Milestone and Royalty Income Through Partnerships with Pharmaceutical Companies
First written in FY2024. 4 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-08-14.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In the joint research with Ono Pharmaceutical Co., Ltd. (hereinafter, "Ono Pharmaceutical"), a predetermined milestone was achieved in November 2025, and we received an upfront payment and joint research funding.」
The joint research with Ono Pharmaceutical resulted in the achievement of a milestone and receipt of an upfront payment and joint research funding. As of fiscal year-end, joint research contracts covered 6 companies in Japan and overseas. - FY2025-H1AdvancedAnnual report
「Including the contracts newly signed in the previous fiscal year with Eli Lilly and Company (hereinafter, "Lilly") and Ono Pharmaceutical Co., Ltd. (hereinafter, "Ono Pharmaceutical"), we currently have contracts with 7 pharmaceutical companies in Japan and overseas. Under 4 of these programs, we and our partner companies have formed integrated project teams to conduct drug discovery research. Research is being conducted at the lead compound discovery stage for 1 program and at the hit compound discovery stage for the remaining 3 programs.」
In addition to continuing contracts with 7 pharmaceutical companies, the research stages of 4 partnered programs are described in specific terms. - FY2024First statedAnnual report
「We receive upfront payments, joint research income, milestones based on development progress, and royalties on sales after launch.」
Partnerships with Eisai, Ohara Pharmaceutical, Merck, Boehringer Ingelheim, SERVIER, Roche, Genentech, Lilly, and Ono Pharmaceutical, among others, form the foundation for monetization.